Spots Global Cancer Trial Database for Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients
Official Title: A Phase 1 Study to Evaluate the Potential Pharmacokinetic Interaction Between Entrectinib and Midazolam in Cancer Patients
Study ID: NCT03330990
Conditions
Study Description
Brief Summary: This is an open-label study in advanced solid tumor patients to determine if entrectinib affects the pharmacokinetics of midazolam and any of its pharmacologically active metabolites.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
SCRI-Denver Drug Development Program, Denver, Colorado, United States
Florida Cancer Specialists - Sarasota (North Catttlemen Rd), Sarasota, Florida, United States
Tennessee Oncology, Nashville, Tennessee, United States
Contact Details
Name: Clinical Trials
Affiliation: Hoffmann-La Roche
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
